XON - Intrexon Corporation
| Previous Close | 9.39 |
| Open | 9.35 |
| Bid | 9.05 x 200 |
| Ask | 9.95 x 100 |
| Day's Range | 9.02 - 9.68 |
| 52 Week Range | 8.92 - 20.16 |
| Volume | 842,270 |
| Avg. Volume | 1,604,909 |
| Market Cap | 1.261B |
| Beta (3Y Monthly) | 1.48 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.55 |
| Earnings Date | Feb 27, 2019 - Mar 4, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.50 |
- Yahoo Finance Video•10 days ago
Oil recovers after dropping below $50
Oil made a slight recovery from Thursday morning's lows. Yahoo Finance's Julie Hyman, Adam Shapiro, and Dan Roberts discuss with Benchmark Investments' CEO Kevin Kelly.
- Zacks•yesterday
Why Is Intrexon (XON) Down 31.5% Since Last Earnings Report?
Intrexon (XON) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- GlobeNewswire•9 days ago
New Research: Key Drivers of Growth for Intrexon, Graham, The Walt Disney, Toyota Motor, Atlas Air Worldwide, and SITO Mobile — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Nov. 30, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- PR Newswire•11 days ago
Oxitec Transitioning Friendly™ Self-limiting Mosquitoes to 2nd Generation Technology Platform, Paving Way to New Scalability, Performance and Cost Breakthroughs
OXFORD, England, Nov. 28, 2018 /PRNewswire/ -- Oxitec, Ltd, a UK-based biotechnology company that pioneered the use of biologically-engineered insects for control of disease-spreading Aedes aegypti mosquitoes and crop-destroying agricultural pests, announced today it will be transitioning from its 1st generation self-limiting Friendly™ Aedes aegypti mosquito (also known as "OX513A") to a new Friendly™ Aedes mosquito ("OX5034") that uses Oxitec's 2nd generation technology, allowing the company to focus on advancing its entire mosquito and crop pest portfolios using this next-generation platform. This transition comes after a decade of experience with Oxitec's 1st generation self-limiting Friendly™ Mosquito and after investments made to engineer new core features specifically designed to provide a range of additional benefits for end-users in vector control and agriculture.
- American City Business Journals•18 days ago
‘Not business as usual’: Rockville biotech’s new CEO wants to turn things around
The new chief executive had joined the company in January — after selling his last biotech company for several million dollars.
- Zacks•last month
Intrexon (XON) Reports Narrower-Than-Expected Loss in Q3
Intrexon (XON) incurs narrower-than-expected loss, while revenues miss estimates in the third quarter of 2018.
- ACCESSWIRE•last month
Today's Research Reports on Trending Tickers: Ligand Pharmaceuticals and Intrexon
NEW YORK, NY / ACCESSWIRE / November 9, 2018 / U.S. stocks retreated on Thursday after the Fed left interest rates unchanged and signaled that it would continue to tighten monetary policy at a gradual pace.
- Thomson Reuters StreetEvents•last month
Edited Transcript of XON earnings conference call or presentation 8-Nov-18 10:30pm GMT
Q3 2018 Intrexon Corp Earnings Call
- PR Newswire•last month
Intrexon Announces Third Quarter 2018 Financial Results
GERMANTOWN, Md., Nov. 8, 2018 /PRNewswire/ -- Intrexon Corporation (XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced its third quarter financial results for 2018.
- Benzinga•last month
A Preview Of Intrexon's Q3 Earnings
On Thursday, Nov. 8, Intrexon (NYSE: XON ) will release its latest earnings report. Decipher the announcement with Benzinga's help. Earnings and Revenue Analysts are predicting Intrexon will report a loss ...
- GlobeNewswire•last month
AquaBounty Technologies, Inc. Results for the quarter and nine months ended September 30, 2018
MAYNARD, Mass., Nov. 02, 2018 -- AquaBounty Technologies, Inc. (NASDAQ: AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the.
- PR Newswire•last month
Lifshitz & Miller LLP Announces Investigation of Access National Corporation, Engility Holdings, Inc., Floor & Decor Holdings, Inc., Global Blood Therapeutics, Inc., Intrexon Corporation, Keryx Biopharmaceuticals, Inc., Nevada Gold & Casinos, Inc., and Sonic Corp.
NEW YORK , Nov. 1, 2018 /PRNewswire/ -- Access National Corporation (ANCX) Lifshitz & Miller announces investigation into possible breaches of fiduciary duties in connection with the sale of ANCX to Union ...
- PR Newswire•last month
Intrexon to Announce Third Quarter 2018 Financial Results on November 8th
GERMANTOWN, Md. , Nov. 1, 2018 /PRNewswire/ -- Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, ...
- GlobeNewswire•last month
Bragar Eagel & Squire, P.C. is Investigating Intrexon Corporation (XON) on Behalf of Stockholders and Encourages XON Investors to Contact the Firm
NEW YORK, Oct. 29, 2018 -- Bragar Eagel & Squire, P.C. is investigating potential claims against Intrexon Corporation (NASDAQ: XON). Our investigation concerns whether.
- PR Newswire•last month
ActoBio Therapeutics™ Doses First Patient in Phase Ib/IIa Clinical Study of AG019 for the Treatment of Type 1 Diabetes
A unique approach to induce immune tolerance using specifically targeted and designed ActoBiotics® Lactococcus lactis engineered to express therapeutic agents. GHENT, Belgium, Oct. 29, 2018 /PRNewswire/ -- ActoBio Therapeutics, Inc., a wholly owned subsidiary of Intrexon Corporation (XON) and innovative clinical-stage biotechnology company focused on a new class of microbe-based therapeutic agents, and Intrexon T1D Partners LLC, have announced that the first patient has been dosed in the Company's Phase Ib/IIa clinical trial for the treatment of early onset type 1 diabetes (T1D).
- ACCESSWIRE•last month
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Intrexon Corporation - XON
NEW YORK, NY / ACCESSWIRE / October 25, 2018 / Pomerantz LLP is investigating claims on behalf of investors of Intrexon Corporation (''Intrexon'' or the ''Company'') (XON). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Intrexon and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
- ACCESSWIRE•last month
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Intrexon Corporation (XON)
NEW YORK, NY / ACCESSWIRE / October 25, 2018 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Intrexon Corporation(''Intrexon'' or the ''Company'') (NYSE: ...
- PR Newswire•2 months ago
Intrexon Announces the Formation of Bioinformatics Hub in Munich
Establishing itself as Intrexon Bioinformatics Germany GmbH (IBG) GERMANTOWN, Md. , Oct. 24, 2018 /PRNewswire/ -- Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization ...
- American City Business Journals•2 months ago
Gaithersburg biotech CEO to step down
The chief executive will stay in his role, and on the board, until his successor is appointed or early next year, whichever comes first.
- GlobeNewswire•2 months ago
Report: Exploring Fundamental Drivers Behind Q2, Badger Meter, Tiffany, Walgreens Boots Alliance, Intrexon, and Denali Therapeutics — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Oct. 23, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- PR Newswire•2 months ago
Oxitec to Develop 2nd Friendly™ Mosquito Strain Designed to Combat Malaria-Spreading Mosquitoes
OXFORD, England , October 18, 2018 /PRNewswire/ -- E xpanded collaboration with the Bill & Melinda Gates Foundation will leverage Oxitec ' s Friendly™ biological engineering platform to develop a self-limiting ...
- PR Newswire•2 months ago
Oxitec to Develop 2nd Friendly™ Mosquito Strain Designed to Combat Malaria-Spreading Mosquitoes
OXFORD, England , October 18, 2018 /PRNewswire/ -- E xpanded collaboration with the Bill & Melinda Gates Foundation will leverage Oxitec ' s Friendly™ biological engineering platform to develop a self-limiting ...
- GlobeNewswire•2 months ago
AquaBounty receives construction loan to support development efforts at its Rollo Bay property
AquaBounty Technologies, Inc. (AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the aquaculture market and a majority-owned subsidiary of Intrexon Corporation (XON), announces that the Company’s Canadian subsidiary has received a construction loan in the amount of CA$2.0 million (US$1.6 million) from the Department of Economic Development of the Province of Prince Edward Island. The proceeds of the loan will be used to complete construction of the Company’s 250-metric ton production facility on its Rollo Bay site. The Rollo Bay site, which includes an R&D hatchery, is currently undergoing construction of a 250-metric ton production facility and a broodstock facility. Once complete, 20-30 technical jobs are expected to be added to AquaBounty’s operation.
- GlobeNewswire•2 months ago
INVESTIGATION UPDATE for XON, APOG and ATASY: Levi & Korsinsky, LLP Reminds Investors of Investigations on Behalf of Shareholders
NEW YORK, Oct. 16, 2018 -- Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders of the following publicly-traded companies..
